Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity

BACKGROUND: Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Invest
Main Authors: O’Mara, Alana E., Johnson, James W., Linderman, Joyce D., Brychta, Robert J., McGehee, Suzanne, Fletcher, Laura A., Fink, Yael A., Kapuria, Devika, Cassimatis, Thomas M., Kelsey, Nathan, Cero, Cheryl, Sater, Zahraa Abdul, Piccinini, Francesca, Baskin, Alison S., Leitner, Brooks P., Cai, Hongyi, Millo, Corina M., Dieckmann, William, Walter, Mary, Javitt, Norman B., Rotman, Yaron, Walter, Peter J., Ader, Marilyn, Bergman, Richard N., Herscovitch, Peter, Chen, Kong Y., Cypess, Aaron M.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2020
Teme:
Clinical Medicine
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190915/
https://ncbi.nlm.nih.gov/pubmed/31961826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI131126
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki